Published in Sensors (Basel) on July 08, 2013
Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol (2004) 36.25
Lipid rafts and signal transduction. Nat Rev Mol Cell Biol (2000) 25.87
Semiconductor nanocrystals as fluorescent biological labels. Science (1998) 16.68
Fluorescent proteins from nonbioluminescent Anthozoa species. Nat Biotechnol (1999) 14.64
Primary structure of the Aequorea victoria green-fluorescent protein. Gene (1992) 11.16
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Specific covalent labeling of recombinant protein molecules inside live cells. Science (1998) 9.32
A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A (1996) 8.53
Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol (2002) 7.92
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol (2002) 7.19
Studies on the mechanism by which cyanine dyes measure membrane potential in red blood cells and phosphatidylcholine vesicles. Biochemistry (1974) 6.97
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Visualization of the intracellular behavior of HIV in living cells. J Cell Biol (2002) 6.59
Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol (1991) 6.19
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc (2002) 5.83
Multicolor and electron microscopic imaging of connexin trafficking. Science (2002) 5.60
Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational proteins modification. Proc Natl Acad Sci U S A (1983) 5.12
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci U S A (1996) 4.83
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61
Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol (1996) 4.52
Fluorescence method for measuring the kinetics of fusion between biological membranes. Biochemistry (1984) 4.44
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
Visualizing infection of individual influenza viruses. Proc Natl Acad Sci U S A (2003) 4.10
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00
Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol (1999) 4.00
Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J Virol (1998) 3.94
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat Cell Biol (2001) 3.67
Binding of acylated peptides and fatty acids to phospholipid vesicles: pertinence to myristoylated proteins. Biochemistry (1993) 3.63
Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J Mol Biol (1994) 3.56
Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging. J Virol (2000) 3.54
The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J (1989) 3.50
Herpesviruses use bidirectional fast-axonal transport to spread in sensory neurons. Proc Natl Acad Sci U S A (2001) 3.34
Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology (1991) 3.28
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol (1999) 3.13
Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell (2007) 3.06
An electron microscope study of the early association between two mammalian viruses and their hosts. J Cell Biol (1962) 2.99
Endosome-to-cytosol transport of viral nucleocapsids. Nat Cell Biol (2005) 2.98
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol (2000) 2.85
Pseudotypes of vesicular stomatitis virus with the coat of murine leukaemia and of avian myeloblastosis viruses. J Gen Virol (1972) 2.82
Growth of pseudotypes of vesicular stomatitis virus with N-tropic murine leukemia virus coats in cells resistant to N-tropic viruses. J Virol (1973) 2.75
Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat Struct Biol (2002) 2.66
Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection. J Virol (1999) 2.64
Crystal structure of SIV matrix antigen and implications for virus assembly. Nature (1995) 2.59
Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56
Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology (1999) 2.54
Human hepatitis B vaccine from recombinant yeast. Nature (1984) 2.46
pH-dependent fusion of vesicular stomatitis virus with Vero cells. Measurement by dequenching of octadecyl rhodamine fluorescence. J Biol Chem (1987) 2.46
Receptor binding specificity of recent human H3N2 influenza viruses. Virol J (2007) 2.45
Virus-like particles as immunogens. Trends Microbiol (2003) 2.38
Structural similarity between the p17 matrix protein of HIV-1 and interferon-gamma. Nature (1994) 2.35
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog (2008) 2.32
Binding of peptides with basic residues to membranes containing acidic phospholipids. Biophys J (1991) 2.30
Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther (1998) 2.27
Uncoating of influenza virus in endosomes. J Virol (1984) 2.26
Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol (2004) 2.24
Local modulation of plus-end transport targets herpesvirus entry and egress in sensory axons. Proc Natl Acad Sci U S A (2004) 2.17
gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A (1985) 2.07
Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther (1998) 2.06
Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol (2007) 2.03
Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A (1996) 2.00
Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera. J Virol (2001) 1.98
Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology (2006) 1.97
Heterogeneity of a fluorescent tegument component in single pseudorabies virus virions and enveloped axonal assemblies. J Virol (2005) 1.92
Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J Virol (1986) 1.89
Virus-like particles: passport to immune recognition. Methods (2006) 1.89
Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem (2000) 1.89
Phenotypic mixing of envelope proteins of the parainfluenza virus SV5 and vesicular stomatitis virus. J Virol (1970) 1.85
Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc Natl Acad Sci U S A (2000) 1.81
Conjugation of luminescent quantum dots with antibodies using an engineered adaptor protein to provide new reagents for fluoroimmunoassays. Anal Chem (2002) 1.79
Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J Virol (2002) 1.77
Lipid rafts and pseudotyping. J Virol (2001) 1.75
The protein-labeling reagent FLASH-EDT2 binds not only to CCXXCC motifs but also non-specifically to endogenous cysteine-rich proteins. Pflugers Arch (2001) 1.71
Structural basis for viral late-domain binding to Alix. Nat Struct Mol Biol (2007) 1.69
Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles. Virology (2001) 1.68
Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol (2004) 1.67
In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med (1990) 1.67
Dynamic fluorescent imaging of human immunodeficiency virus type 1 gag in live cells by biarsenical labeling. J Virol (2005) 1.65
Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem (2001) 1.62
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia (2012) 1.60
Visualization of parental HSV-1 genomes and replication compartments in association with ND10 in live infected cells. EMBO J (2002) 1.57
Simultaneous tracking of capsid, tegument, and envelope protein localization in living cells infected with triply fluorescent herpes simplex virus 1. J Virol (2008) 1.56
Fluorescent cell labeling for in vivo and in vitro cell tracking. Methods Cell Biol (1990) 1.55
Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci U S A (1997) 1.53
COOH-terminal requirements for the correct processing of a phosphatidylinositol-glycan anchored membrane protein. J Biol Chem (1988) 1.52
Modulating the function of the measles virus RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open reading frame. J Virol (2002) 1.51
Recruitment of herpes simplex virus type 1 transcriptional regulatory protein ICP4 into foci juxtaposed to ND10 in live, infected cells. J Virol (2003) 1.50
Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J Virol (2005) 1.49
Double-labelled HIV-1 particles for study of virus-cell interaction. Virology (2006) 1.49
Virus receptor interaction in the adenovirus system. II. Capping and cooperative binding of virions on HeLa cells. J Virol (1983) 1.48
Filoviruses: Interactions with the host cell. Cell Mol Life Sci (2008) 1.48
Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol (2005) 1.47
Optical coding of mammalian cells using semiconductor quantum dots. Anal Biochem (2004) 1.46
Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol (1993) 1.45
Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol (2004) 2.23
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood (2011) 2.14
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol (2003) 2.08
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol (2009) 1.71
EMPACT syndrome. J Dtsch Dermatol Ges (2005) 1.41
Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma (2006) 1.39
Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. Blood (2010) 1.20
Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica (2012) 1.18
TIM-3 does not act as a receptor for galectin-9. PLoS Pathog (2013) 1.15
Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant (2008) 1.14
No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol (2006) 1.13
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res (2010) 1.10
The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol (2008) 1.09
Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J (2012) 1.07
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood (2009) 1.04
B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ. Blood (2013) 1.02
CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep (2013) 1.02
T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. J Immunol Methods (2010) 1.02
General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol (2007) 1.01
Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients. Blood (2009) 1.00
Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res (2006) 0.98
Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol (2013) 0.95
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood (2011) 0.94
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J (2005) 0.93
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol (2007) 0.92
Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci U S A (2006) 0.92
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica (2007) 0.91
CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood (2013) 0.90
Interaction of allergens, major histocompatibility complex molecules, and T cell receptors: a 'ménage à trois' that opens new avenues for therapeutic intervention in type I allergy. Int Arch Allergy Immunol (2011) 0.89
Laminin modulates morphogenic properties of the collagen XVIII endostatin domain. J Biol Chem (2002) 0.86
Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol (2006) 0.86
The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. Immunol Lett (2011) 0.85
Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res (2009) 0.85
In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol (2010) 0.84
Human TCR transgenic Bet v 1-specific Th1 cells suppress the effector function of Bet v 1-specific Th2 cells. J Immunol (2011) 0.84
Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood (2007) 0.83
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica (2011) 0.83
Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner. J Allergy Clin Immunol (2011) 0.83
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol (2008) 0.83
The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol (2013) 0.83
5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood (2012) 0.82
Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. J Allergy Clin Immunol (2009) 0.82
The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood (2006) 0.81
Characterization of HLA class II/peptide-TCR interactions of the immunodominant T cell epitope in Art v 1, the major mugwort pollen allergen. J Immunol (2008) 0.81
KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Exp Hematol (2010) 0.81
Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Blood (2009) 0.81
Lipid rafts, pseudotyping, and virus-like particles: relevance of a novel, configurable, and modular antigen-presenting platform. Int Arch Allergy Immunol (2010) 0.80
Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions. FASEB J (2010) 0.79
Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol (2007) 0.79
Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels. Int Arch Allergy Immunol (2010) 0.79
Costimulatory signals potently modulate the T cell inhibitory capacity of the therapeutic CD11a antibody Efalizumab. Clin Immunol (2011) 0.78
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Vet Immunol Immunopathol (2009) 0.78
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol (2010) 0.78
On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy). Int Arch Allergy Immunol (2016) 0.78
Host-encoded reporters for the detection and purification of multiple enveloped viruses. J Virol Methods (2010) 0.77
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. Oncotarget (2014) 0.77
Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp Hematol (2008) 0.77
A novel immunodeficiency syndrome associated with partial trisomy 19p13. J Med Genet (2014) 0.76
Lymphocyte-based model systems for allergy research: a historic overview. Int Arch Allergy Immunol (2014) 0.76
The value of identifying major T cell epitopes of clinically important allergens. Int Arch Allergy Immunol (2012) 0.75
Comprehensive comparative and semiquantitative proteome of a very low number of native and matched epstein-barr-virus-transformed B lymphocytes infiltrating human melanoma. J Proteome Res (2014) 0.75
Years in Review: Recent Progress in Cellular Allergology. Int Arch Allergy Immunol (2016) 0.75